This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
by Kinjel Shah
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $131.17, moving +1.25% from the previous trading session.
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
by Zacks Equity Research
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Theravance Announces Positive Early Data on JAK Inhibitor
by Zacks Equity Research
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation
by Zacks Equity Research
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease
by Zacks Equity Research
Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
J&J's Stelara Gets Approval in EU for Ulcerative Colitis
by Zacks Equity Research
Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $128.86, marking a +0.09% move from the previous day.
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
Allergan Settles Ahead of Multi-District Opioid Litigation
by Zacks Equity Research
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry
by Zacks Equity Research
Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
by Christopher Vargas
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
Johnson and Johnson Opioid Lawsuit and More Doom and Gloom
by Panel Of Zacks Experts
The market bounces back while Erique and Danny talk about Whiskey, Johnson and Johnson and continued trade war. The portfolios stay put while showing a lot of green, see what happens on this episode of Paper Traders.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $129.64 in the latest trading session, marking a +1.44% move from the prior day.